124 related articles for article (PubMed ID: 19125088)
1. Successful treatment of hodgkin lymphoma in nijmegen breakage syndrome.
Jovanovic A; Minic P; Scekic-Guc M; Djuricic S; Cirkovic S; Weemaes C; Pasic S
J Pediatr Hematol Oncol; 2009 Jan; 31(1):49-52. PubMed ID: 19125088
[TBL] [Abstract][Full Text] [Related]
2. Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: a progress report.
Sagar TG; Chandra A; Raman SG
Med Pediatr Oncol; 2003 Jan; 40(1):66-9. PubMed ID: 12426693
[No Abstract] [Full Text] [Related]
3. Hodgkin s disease with nephrotic syndrome as a complication of ulcerative colitis: case report.
Basić-Jukić N; Radman I; Roncević T; Jakić-Razumović J
Croat Med J; 2002 Oct; 43(5):573-5. PubMed ID: 12402399
[TBL] [Abstract][Full Text] [Related]
4. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
5. [Successful chemotherapy of cancer. Remission of Hodgkin's disease. IV].
Lopez M
Clin Ter; 2001; 152(3):203-6. PubMed ID: 11692542
[No Abstract] [Full Text] [Related]
6. Long-term outcome of children and adolescents treated with the COPP-ABV hybrid protocol for Hodgkin's disease: balance of risks.
Klumb CE; Carriço MK; de Rezende LM; Byington R; Bordallo MA; Bigni RS; Apa AG; Dobbin JA
Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):628-9. PubMed ID: 17662581
[No Abstract] [Full Text] [Related]
7. [Initial results of hybrid chemotherapy of Hodgkin's disease using COPP/VBA].
Schneider T; Molnár Z; Szántó I; Fleischmann T
Orv Hetil; 1992 Oct; 133(43):2755-7. PubMed ID: 1383907
[TBL] [Abstract][Full Text] [Related]
8. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two non-cross-resistant combinations (ABVP/LOPP) with COPP plus bleomycin in the treatment of advanced Hodgkin's disease.
Koza I; Bohunický L; Mociková K; Gyárfás J; Svancárová L; Mardiak J; Spánik S; Fuchsberger P; Thalmeinerová Z; Sufliarsky J
Neoplasma; 1991; 38(6):583-93. PubMed ID: 1722564
[TBL] [Abstract][Full Text] [Related]
10. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
11. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
12. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
[TBL] [Abstract][Full Text] [Related]
13. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
14. Vanishing bile duct syndrome and Hodgkin disease: a case series and review of the literature.
Pass AK; McLin VA; Rushton JR; Kearney DL; Hastings CA; Margolin JF
J Pediatr Hematol Oncol; 2008 Dec; 30(12):976-80. PubMed ID: 19131796
[TBL] [Abstract][Full Text] [Related]
15. Greater curability in advanced Hodgkin's disease?
Portlock CS
Cancer J Sci Am; 1999; 5(5):264-5. PubMed ID: 10526665
[No Abstract] [Full Text] [Related]
16. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
17. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
18. Hodgkin's lymphoma--the great teacher.
Connors JM
N Engl J Med; 2011 Jul; 365(3):264-5. PubMed ID: 21774715
[No Abstract] [Full Text] [Related]
19. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067
[TBL] [Abstract][Full Text] [Related]
20. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]